Small cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis. Tarlatamab, a bispecific T cell engager that targets CD3 and delta-like ligand 3 (DLL3), is the standard of care for patients with previously treated SCLC. However, the mechanisms underlying acquired tarlatamab resistance remain unclear.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 26 Mar 2026.
The item focuses on Brief Report: Low Delta-like Ligand 3 expression and T Cell Exhaustion Drive Resistance to Tarlatamab combined with anti-PD-1 in Small-Cell Lung Cancer.
Review the original article for the full source wording and details.